Overview
- Pfizer will pay $65.60 per share in cash plus contingent value rights worth up to $20.65, for a potential total of $86.25 per share.
- Metsera’s board cited FTC concerns about the legal risks of Novo Nordisk’s two‑step offer, including the possibility that an initial dividend might never be paid or could be rescinded.
- Novo Nordisk said it will not raise its bid further and is exiting the pursuit, pointing to price discipline and antitrust exposure.
- Metsera’s directors reaffirmed support for the Pfizer deal ahead of a Nov. 13 shareholder vote, and the companies expect to close promptly afterward with FTC clearance already in hand.
- The deal gives Pfizer a foothold in the fast‑growing obesity‑drug market even as Metsera’s programs remain years from approval, with shares up about 60% this week and analysts split on long‑term revenue potential.